# OnCo record nct07655622 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07655622/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07655622", "NCT07655622" ;
  schema:name "Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression"@en ;
  schema:alternateName "DUAL-THRUST"@en ;
  schema:description "A phase 1/2 trial of vebreltinib in lung cancer, run by Second Affiliated Hospital of Nanchang University, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07655622/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07655622> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/vebreltinib/> ;
  onco:companies <https://onco.cc/companies/beijing-pearl-biotechnology-limited-liability-company/> .